National University of Singapore

Singapore Health Services Pte Ltd

60 Degrees Pharmaceuticals, LLC

Massachusetts Institute of Technology

Satoru Watanabe

Eng Eong Ooi

Subhash G Vasudevan

Geoffrey Stuart Dow

Jenny Low

Abhay Rathore

Cynthia Sung

Mark Reid

Glynn Morrish

Ram Sasisekharan

Kannan Tharakaraman

Kuan Rong Chan

Kitti Wing Ki Chan

Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Antibodies that bind zika virus envelope protein and uses thereof

Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.

Dosing regimens of celgosivir for the treatment of dengue

Methods of preventing a disease resulting from a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I); a compound of Formula (I) can be first administered to an asymptomatic human subject followed by subsequent doses administered at least once daily. The methods of the invention can be used to prevent a disease resulting from primary and secondary DENV 1-4 viral infections. 

Dosing regimens of celgosivir for the prevention of dengue

Antibodies that bind Zika virus envelope protein and uses thereof

Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV 1-4 viral infections.

Dosing regiments of celgosivir for the treatment of dengue

Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections. 

Growing community of inventors

Singapore, Singapore

Satoru Watanabe